Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
AbbVie Analyst Ratings
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Express News | Abbvie : Piper Sandler Raises Target Price to $209 From $196
In One Chart | Wall Street Eyes New Sectors for the Next Stock Market Surge
The 20 Most Popular Mutual Fund Increases During 2Q - Goldman Sachs
Unpacking the Latest Options Trading Trends in AbbVie
FTC Says FDA Biosimilar Guidance Would Increase Competition, Lead to Lower Prices
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use
ABBV.US's potential blockbuster bispecific antibody therapy has once again been approved by the European Union.
On August 20th, AbbVie (ABBV.US) and genmab (GMAB.US) jointly announced that the European Commission has approved Tepkinly (epcoritamab) for expanded indications for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) in adult patients.
EC Approves AbbVie's TEPKINLY for Follicular Lymphoma
AbbVie's Tepkinly Gets Conditional EU Approval For Relapsed Or Refractory Follicular Lymphoma
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
AbbVie, Genmab Lymphoma Treatment Gets European Commission Marketing Authorization
NYSE New 52-Week Highs And Lows
Express News | European Commission Grants Second Indication Approval for Tepkinly® (Epcoritamab) for the Treatment of Adults With Relapsed/Refractory Follicular Lymphoma
AbbVie Hits All-time High
European Commission Grants Second Indication Approval for TEPKINLY (Epcoritamab) for the Treatment of Adults With Relapsed/Refractory Follicular Lymphoma